Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab combined with TAS-102 as second-line treatment for advanced colorectal cancer
ChiCTR2200058610Phase 2Not yet recruiting
- Sponsor
- Xuchang Central Hospital
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Xuchang Central Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
bevacizumabtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200058610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058610.